209 related articles for article (PubMed ID: 23145925)
1. Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study.
Prosperi MC; Fabbiani M; Fanti I; Zaccarelli M; Colafigli M; Mondi A; D'Avino A; Borghetti A; Cauda R; Di Giambenedetto S
BMC Infect Dis; 2012 Nov; 12():296. PubMed ID: 23145925
[TBL] [Abstract][Full Text] [Related]
2. First-line antiretroviral drug discontinuations in children.
Fortuin-de Smidt M; de Waal R; Cohen K; Technau KG; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA
PLoS One; 2017; 12(2):e0169762. PubMed ID: 28192529
[TBL] [Abstract][Full Text] [Related]
3. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
Miro JM; Manzardo C; Ferrer E; Loncà M; Guardo AC; Podzamczer D; Domingo P; Curran A; Clotet B; Cruceta A; Lozano F; Pérez I; Plana M; Gatell JM;
J Acquir Immune Defic Syndr; 2015 Jun; 69(2):206-15. PubMed ID: 25831464
[TBL] [Abstract][Full Text] [Related]
4. Adverse Drug Reactions Among Patients Initiating Second-Line Antiretroviral Therapy in South Africa.
Onoya D; Hirasen K; van den Berg L; Miot J; Long LC; Fox MP
Drug Saf; 2018 Dec; 41(12):1343-1353. PubMed ID: 30043384
[TBL] [Abstract][Full Text] [Related]
5. Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
Di Biagio A; Prinapori R; Giannarelli D; Maggiolo F; Di Giambenedetto S; Borghi V; Penco G; Cicconi P; Francisci D; Sterrantino G; Zoncada A; Monno L; Capetti A; Giacometti A;
J Antimicrob Chemother; 2013 Jan; 68(1):200-5. PubMed ID: 22915463
[TBL] [Abstract][Full Text] [Related]
6. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.
Robbins GK; De Gruttola V; Shafer RW; Smeaton LM; Snyder SW; Pettinelli C; Dubé MP; Fischl MA; Pollard RB; Delapenha R; Gedeon L; van der Horst C; Murphy RL; Becker MI; D'Aquila RT; Vella S; Merigan TC; Hirsch MS;
N Engl J Med; 2003 Dec; 349(24):2293-303. PubMed ID: 14668455
[TBL] [Abstract][Full Text] [Related]
7. Treatment Discontinuation in Adult HIV-Infected Patients on First-Line Antiretroviral Therapy in Nigeria.
Agbaji OO; Abah IO; Falang KD; Ebonyi AO; Musa J; Ugoagwu P; Agaba PA; Sagay AS; Jolayemi T; Okonkwo P; Idoko JA; Kanki PJ
Curr HIV Res; 2015; 13(3):184-92. PubMed ID: 25986369
[TBL] [Abstract][Full Text] [Related]
8. Incidence and predictors of Adverse Drug Reaction (ADR) among adult HIV positive patients on anti-retroviral treatment in Arba Minch town public health facilities, southern Ethiopia: A retrospective cohort study, 2020.
Sherfa A; Haile D; Yihune M; Sako S
PLoS One; 2021; 16(5):e0251763. PubMed ID: 34043687
[TBL] [Abstract][Full Text] [Related]
9. Routine data underestimates the incidence of first-line antiretroviral drug discontinuations due to adverse drug reactions: Observational study in two South African cohorts.
de Waal R; Cohen K; Boulle A; Fox MP; Maartens G; Igumbor EU; Davies MA
PLoS One; 2018; 13(9):e0203530. PubMed ID: 30183766
[TBL] [Abstract][Full Text] [Related]
10. Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy.
Jose S; Quinn K; Hill T; Leen C; Walsh J; Hay P; Fisher M; Post F; Nelson M; Gompels M; Johnson M; Chadwick D; Gilson R; Sabin C; Fidler S;
AIDS; 2014 Jun; 28(9):1333-9. PubMed ID: 24583670
[TBL] [Abstract][Full Text] [Related]
11. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.
Cicconi P; Cozzi-Lepri A; Castagna A; Trecarichi EM; Antinori A; Gatti F; Cassola G; Sighinolfi L; Castelli P; d'Arminio Monforte A;
HIV Med; 2010 Feb; 11(2):104-13. PubMed ID: 19732176
[TBL] [Abstract][Full Text] [Related]
12. The influence of patient beliefs and treatment satisfaction on the discontinuation of current first-line antiretroviral regimens.
Casado JL; Marín A; Romero V; Bañón S; Moreno A; Perez-Elías MJ; Moreno S; Rodriguez-Sagrado MA
HIV Med; 2016 Jan; 17(1):46-55. PubMed ID: 26149493
[TBL] [Abstract][Full Text] [Related]
13. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
[TBL] [Abstract][Full Text] [Related]
14. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.
Labarga P; Soriano V; Vispo ME; Pinilla J; Martin-Carbonero L; Castellares C; Casado R; Maida I; Garcia-Gasco P; Barreiro P
J Infect Dis; 2007 Sep; 196(5):670-6. PubMed ID: 17674307
[TBL] [Abstract][Full Text] [Related]
15. Antiretroviral Therapy-associated Adverse Drug Reactions and their Effects on Virologic Failure- A Retrospective Cohort Study in Nigeria.
Abah IO; Ncube NBQ; Bradley HA; AgbaJi OO; Kanki P
Curr HIV Res; 2018; 16(6):436-446. PubMed ID: 30767743
[TBL] [Abstract][Full Text] [Related]
16. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
Carr A; Chuah J; Hudson J; French M; Hoy J; Law M; Sayer D; Emery S; Cooper DA
AIDS; 2000 Jun; 14(9):1171-80. PubMed ID: 10894281
[TBL] [Abstract][Full Text] [Related]
17. Incidence and predictors of regimen-modification from first-line antiretroviral therapy in Thailand: a cohort study.
Tsuchiya N; Pathipvanich P; Wichukchinda N; Rojanawiwat A; Auwanit W; Ariyoshi K; Sawanpanyalert P
BMC Infect Dis; 2014 Oct; 14():565. PubMed ID: 25361850
[TBL] [Abstract][Full Text] [Related]
18. Monotherapy with boosted PIs as an ART simplification strategy in clinical practice.
Santos JR; Llibre JM; Berrio-Galan D; Bravo I; Miranda C; Pérez-Alvarez S; Pérez-Alvarez N; Paredes R; Clotet B; Moltó J
J Antimicrob Chemother; 2015 Apr; 70(4):1124-9. PubMed ID: 25525196
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.
Bongiovanni M; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Bini T; Monforte Ad
Int J Antimicrob Agents; 2005 Jul; 26(1):88-91. PubMed ID: 15878262
[TBL] [Abstract][Full Text] [Related]
20. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.
Palmer M; Chersich M; Moultrie H; Kuhn L; Fairlie L; Meyers T
AIDS; 2013 Mar; 27(5):781-5. PubMed ID: 23169331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
